For Clinicians

Numerous published studies—spanning more than 36,000 patients—have demonstrated that the level of ST2 in blood can predict chronic heart failure patient outcomes.

Measuring ST2 via a simple, non-invasive blood test allows for the early identification of chronic heart failure patients at highest risk for re-hospitalization and mortality versus those at lower risk.

ST2 levels change rapidly in response to changes in the patient’s condition, and when used in conduction with other clinical parameters, helping you to focus on patients requiring immediate medical attention.

ST2 levels are not adversely affected by such factors as age, gender, BMI, atrial fibrillation, history of heart failure, anemia, and impaired renal function.

ST2 has a single cutpoint, removing any guesswork, making treatment decisions easier.

There are several ways in which results from ST2 testing can be useful in chronic heart failure patient management including:

Focused Outpatient Care

Focused planning for heart failure patients can reduce costly hospital readmissions.

Unlike many other cardiac biomarkers, ST2 levels change quickly and signficantly in response to changes in the patient’s condition—thus helping physicians make informed decisions on an appropriate course of action to take, and if needed, to quickly adjust care, improving patient outcomes and optimizing the interval between patient visits.

Clinicians that use ST2 as part of a patient management program can potentially impact 30-day rehospitalization and mortality rates for patients with chronic heart failure.

Assessing Referrals

ST2 can be used to assess which patients are at highest risk for adverse events and therefore should be referred to a specialist.

If You’re Interested in Conducting A Clinical Trial Involving ST2

To find out about purchasing purchasing kits for a clinical study, please contact us at or call 877.700.1250.